PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28821198
OWN - NLM
STAT- MEDLINE
DA  - 20170819
DCOM- 20170906
LR  - 20170906
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 148
IP  - 3
DP  - 2017 Sep 01
TI  - CD200 Expression in Neuroendocrine Neoplasms.
PG  - 236-242
LID - 10.1093/ajcp/aqx071 [doi]
AB  - Objectives: CD200 expression has been well studied in hematopoietic malignancies;
      however, CD200 expression has not been well-characterized in neuroendocrine
      neoplasms. We examined CD200 expression in 391 neuroendocrine neoplasms from
      various anatomic sites. Methods: Tissue blocks containing pulmonary small cell
      carcinoma, pulmonary carcinoid, large cell neuroendocrine carcinoma, pancreatic
      neuroendocrine tumor, gastrointestinal carcinoid, and Merkel cell carcinoma were 
      evaluated for CD200 expression by immunohistochemistry. A set of
      nonneuroendocrine carcinomas was stained for comparison. Results: CD200 was
      expressed in 87% of the neuroendocrine neoplasms studied, including 60 of 72
      (83%) pulmonary small cell carcinomas, 15 of 22 (68%) pulmonary carcinoids, three
      of four (75%) pulmonary large cell neuroendocrine carcinomas, 125 of 146 (86%)
      Merkel cell carcinomas, 79 of 83 (95%) gastrointestinal luminal carcinoids, and
      56 of 60 (93%) pancreatic neuroendocrine tumors. Thirty-two of 157 (20%)
      nonneuroendocrine carcinomas expressed CD200. In gastrointestinal carcinoid and
      pancreatic neuroendocrine neoplasms, CD200 negativity correlated with higher
      grade. Conclusions: CD200 is a relatively sensitive marker of neuroendocrine
      neoplasms and represents a potential therapeutic target in these
      difficult-to-treat malignancies.
FAU - Love, Jason E
AU  - Love JE
AD  - Western Washington Pathology, Tacoma.
FAU - Thompson, Kimberly
AU  - Thompson K
AD  - PhenoPath Laboratories, Seattle, WA.
FAU - Kilgore, Mark R
AU  - Kilgore MR
AD  - Department of Pathology.
FAU - Westerhoff, Maria
AU  - Westerhoff M
AD  - Department of Pathology.
FAU - Murphy, Claire E
AU  - Murphy CE
AD  - Department of Pathology.
FAU - Papanicolau-Sengos, Antonios
AU  - Papanicolau-Sengos A
AD  - OmniSeq, Buffalo, NY.
FAU - McCormick, Kinsey A
AU  - McCormick KA
AD  - Medical Oncology.
FAU - Shankaran, Veena
AU  - Shankaran V
AD  - Medical Oncology.
FAU - Vandeven, Natalie
AU  - Vandeven N
AD  - Medicine and Dermatology.
FAU - Miller, Faith
AU  - Miller F
AD  - MultiCare Health System, Tacoma, WA.
FAU - Blom, Astrid
AU  - Blom A
AD  - Medicine and Dermatology.
FAU - Nghiem, Paul T
AU  - Nghiem PT
AD  - Medicine and Dermatology.
FAU - Kussick, Steven J
AU  - Kussick SJ
AD  - PhenoPath Laboratories, Seattle, WA.
AD  - Laboratory Medicine, University of Washington, Seattle.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Antigens, CD)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (antigens, CD200)
SB  - AIM
SB  - IM
MH  - Antigens, CD/*metabolism
MH  - Biomarkers, Tumor/metabolism
MH  - Carcinoma, Merkel Cell/*metabolism/pathology
MH  - Gastrointestinal Neoplasms/*metabolism/pathology
MH  - Humans
MH  - Lung Neoplasms/*metabolism/pathology
MH  - Neuroendocrine Tumors/*metabolism/pathology
MH  - Pancreatic Neoplasms/*metabolism/pathology
OTO - NOTNLM
OT  - CD200
OT  - Immunohistochemistry
OT  - Neuroendocrine neoplasms
EDAT- 2017/08/20 06:00
MHDA- 2017/09/07 06:00
CRDT- 2017/08/20 06:00
AID - 4080650 [pii]
AID - 10.1093/ajcp/aqx071 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2017 Sep 1;148(3):236-242. doi: 10.1093/ajcp/aqx071.